Find Funding Opportunities

This FOA encourages applications for biomarker validation trials or exploratory clinical trials of drugs, biologics, surgical therapies or devices that may contribute to the justification for and provide the data required to design a future trial to confirm efficacy (i.e., a Phase III trial) in the treatment of neurologic disease. Applications for drugs or biologics should provide compelling scientific evidence that the investigational agent proposed for study will reach/act upon the designated target or that its mechanism of action is such that it will be of benefit in ameliorating a specific aspect of the disease. Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. Applicants do not need to be part of the existing NeuroNEXT infrastructure.

This FOA encourages proposals for biomarker validation trials or exploratory clinical trials of drugs, biologics, surgical therapies or devices that may contribute to the justification for and provide the data required to design a future trial to confirm efficacy (i.e., a Phase III trial) in the treatment of neurologic disease. Proposals for drugs or biologics should provide compelling scientific evidence that the investigational agent proposed for study will reach/act upon the designated target or that its mechanism of action is such that it will be of benefit in ameliorating a specific aspect of the disease.

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose biomarker validation trials or exploratory clinical trials of drugs, biologics, surgical therapies or devices for neurological disorders which may contribute to the justification for and provide the data required to design a future trial to confirm efficacy (i.e., a Phase III clinical trial) in the treatment of neurologic disease. The program will utilize the cooperative agreement mechanism to enable milestone-drive projects.

The purpose of this funding opportunity announcement (FOA), issued by NINDS, is to invite new and renewal applications to participate as Clinical Site Hubs in the Neurological Emergencies Treatment Trials (NETT) Network.The goal of this existing network is to develop and widely implement efficacious treatments for patients with a broad spectrum of neurological emergencies in order to decrease the morbidity and mortality associated with neurological disease.Their objective is to conduct multiple, large, streamlined phase III clinical trials involving neurological emergencies.

This Funding Opportunity Announcement (FOA), issued as part of the NIH Basic Behavioral and Social Sciences Opportunity Network (OppNet), encourages research grant applications that propose to increase understanding of the basic cognitive, affective, motivational, and social processes that underlie decision making across the lifespan.This includes an appreciation of the interactions among the psychological, neurobiological, and behavioral processes in decision making.It also includes consideration of the mediating and/or moderating influences of genetics, physiology, the social environment, and culture.

The purpose of this funding opportunity announcement (FOA) issued by NINDS is to solicit applications to support a national program of mentored advanced research career development for junior neurosurgeon faculty at institutions nationwide that support neurosurgical research. The goal of the program is to expand the cadre of neurosurgeon-researchers who will combine their clinical and research expertise to conduct research into neurological disorders that neurosurgeons are uniquely qualified to conduct.

This funding opportunity announcement (FOA) encourages research grant applications from institutions/organizations to develop novel, robust analytical platforms using in vitro assays to reveal changes in neuronal and/or glial function. The goal is to adapt state-of-the-art measures of basic cellular processes or molecular events that are key mediators of nervous system function with the intent to probe mechanisms and/or perturbations in an unbiased and efficient manner. The novel assay platforms would provide opportunities to measure neurobiological endpoints and build a pipeline to be used in the context of target identification and drug discovery.

This NIH Funding Opportunity Announcement (FOA), supported by funds from the NIH Common Fund (Common Fund) and participating NIH Institute(s) and Center(s), invites applications from foreign Institutions in African countries who wish to develop the study of genomic/genetic/environmental contributors of human health and disease within Africa, using cutting edge research tools to understand health and diseases affecting African populations more completely and increase capacity for biomedical research, in terms of building infrastructure (including data and research resources), genomic proficiency of researchers and numbers of trainees. In partnership with the Wellcome Trust, the H3Africa initiative is focused on supporting these efforts as part of an effort to promote sustainable research in Africa that will promote health and combat disease.

This NIH Funding Opportunity Announcement (FOA), supported by funds from the NIH Common Fund (Common Fund) and participating NIH Institute(s) and Center(s), invites applications from foreign Institutions in African countries who wish to develop the study of genomic/genetic/environmental contributors of human health and disease within Africa, using cutting edge research tools to understand health and diseases affecting African populations more completely and increase capacity for biomedical research, in terms of building infrastructure (including data and research resources), genomic proficiency of researchers and numbers of trainees. In partnership with the Wellcome Trust, the H3Africa initiative is focused on supporting these efforts as part of an effort to promote sustainable research in Africa that will promote health and combat disease.

This Funding Opportunity Announcement (FOA) solicits Research Program Project Grant (P20) applications from institutions/organizations proposing exploratory collaborative research on disease modification or prevention in an epilepsy syndrome. Successful exploratory studies may lead to subsequent applications for support of a collaborative, multidisciplinary Epilepsy Center without Walls on Disease Modification and Prevention. Depending on the topic area, however, exploratory studies may alternatively lead to applications for the NINDS Translational Program for Resistant Epilepsy and Epileptogenesis, the NINDS Clinical Trials Program, or additional investigator initiated research programs. This FOA is for support of new projects, not continuation of projects that have already been initiated. Interventional clinical trials are also not appropriate for this FOA.